Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.
about
Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaSignificance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission.Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testingMinimal residual disease following allogeneic hematopoietic stem cell transplantation.Recent advancements of flow cytometry: new applications in hematology and oncology.Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adultsThe addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.Application of flow cytometry in pediatric hematology-oncology.Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia.Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation.New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL.Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide.Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia.A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD).Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
P2860
Q26751269-E216E7F7-A817-40BF-9520-74DC4D0C8C1FQ33931553-969486B8-0955-4CF7-829A-977FF49484F9Q34425875-42566A31-11B4-4B31-B594-5E3992895542Q34667390-D1F445C0-EE0A-4F95-926F-C04F25D558D8Q35059549-FAE86AB3-B4A6-47F3-976E-3D94CA7038B4Q36100435-03ECB5CE-D84A-451D-B895-96BF4EE8651AQ36461915-02BC5C5A-2D77-4F47-876B-EADC16528FE7Q37670062-C14D9106-0FC6-41C6-8B4A-5D3145B39F7FQ37861074-EDA6A2D6-5D86-478F-B9AF-54895BB9FF92Q38028808-AE258E83-5ABB-49CD-9A5F-EF7FA42C4FF4Q38105123-CECB3431-32E6-427D-B72D-5D8FAB16DC29Q38220573-216B7777-A9B9-498F-A349-2A246C8AA1C4Q38669037-8B0AFB43-0D7D-4CBF-AE17-684A0F243612Q38756821-E2F725DD-66B1-475D-B916-1793AE7852E5Q39420711-FB8241B5-DFF4-4A6B-9BB1-3D9C721E8809Q47614484-E2B2081C-C4C1-4463-B2BD-BA77CABE597CQ48762439-1ED7862C-830A-4BB7-BB24-8DF8A5A08243
P2860
Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Relationship between minimal r ...... acute lymphoblastic leukemia.
@ast
Relationship between minimal r ...... acute lymphoblastic leukemia.
@en
type
label
Relationship between minimal r ...... acute lymphoblastic leukemia.
@ast
Relationship between minimal r ...... acute lymphoblastic leukemia.
@en
prefLabel
Relationship between minimal r ...... acute lymphoblastic leukemia.
@ast
Relationship between minimal r ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P1433
P1476
Relationship between minimal r ...... h acute lymphoblastic leukemia
@en
P2093
Izaskun Elorza
Jose Luis Dapena
José Sánchez de Toledo
Laura Gallur
P2860
P304
P356
10.3324/HAEMATOL.2009.010843
P577
2010-02-23T00:00:00Z